Global Home Infusion Therapy Market Size and Forecast 2025–2033: Healthcare Moves Closer to Home

Introduction: A New Era of Care Beyond Hospital Walls

Healthcare delivery is undergoing a fundamental shift. As hospitals face increasing pressure from rising patient volumes, workforce shortages, and cost constraints, more care is being transferred into the home. One of the fastest-growing segments of this transformation is home infusion therapy, a model of care that enables patients to receive intravenous medications, fluids, and nutrition in the comfort of their own homes.

According to Renub Research, the Global Home Infusion Therapy Market is expected to grow from US$ 45.28 billion in 2024 to US$ 77.34 billion by 2033, registering a CAGR of 6.13% from 2025 to 2033. This growth reflects not only technological advancement but also changing patient expectations, evolving reimbursement models, and the rising prevalence of chronic diseases worldwide.

Download Free Sample Report

Home infusion therapy is no longer a niche service—it is rapidly becoming a core component of modern healthcare systems.

What Is Home Infusion Therapy and Why It Matters

Home infusion therapy involves administering medications, fluids, or nutrients directly into a patient’s bloodstream through an intravenous (IV) line outside of a traditional clinical setting. These therapies are often used for patients requiring long-term treatment for chronic conditions such as cancer, autoimmune disorders, infections, gastrointestinal diseases, and metabolic conditions.

While healthcare professionals oversee the treatment, many patients and caregivers are trained to safely manage infusion processes at home. This approach offers several advantages:

Reduced hospital stays and readmissions

Lower overall treatment costs

Greater patient comfort and convenience

Improved adherence to long-term therapies

Better quality of life and outcomes

The growing acceptance of home-based care is reshaping healthcare delivery models globally.

Rising Demand Fueled by Aging Populations and Chronic Disease Burden

One of the strongest growth drivers of the home infusion therapy market is the rapid rise in chronic illnesses. Conditions such as diabetes, cancer, cardiovascular diseases, autoimmune disorders, and neurological diseases often require long-term or recurring intravenous therapies. Managing these patients in hospitals is expensive and resource-intensive, making home-based alternatives more attractive.

At the same time, the global aging population is expanding at an unprecedented rate. Older adults are more likely to require infusion-based therapies but also prefer to receive care at home rather than in institutional settings. This demographic shift alone is creating sustained demand for home infusion services across developed and emerging markets.

Healthcare Cost Pressures Accelerate Adoption

Healthcare systems worldwide are under immense financial strain. Home infusion therapy offers a cost-effective alternative to inpatient care, often reducing expenses by 30–60% compared to hospital-based infusion treatments.

In the United States, for example, home health services are covered under Medicare, encouraging hospitals and insurers to transition suitable patients to home-based care. The Research Institute for Home Care (RIHC) reported that there were 11,353 active home health agencies in the U.S. in 2022, highlighting the scale of this shift.

Governments and insurers increasingly recognize home infusion therapy as a strategic tool to reduce hospitalization costs while maintaining care quality.

Technology Is Redefining Home Infusion Therapy

Technological innovation is one of the most transformative forces in this market. Modern home infusion therapy is powered by smart infusion pumps, safety software, remote monitoring tools, and digital health platforms that enable precise and secure treatment delivery at home.

Digital Health Integration

Connected devices now allow healthcare providers to remotely monitor infusion progress, detect errors, and adjust therapy plans in real time. This improves patient safety while reducing the need for frequent in-person visits.

In May 2024, Moog received U.S. FDA approval for the CURLIN 8000 ambulatory infusion system, designed specifically for home infusion therapy. The system integrates with CURLIN RxManager software, enhancing safety and control for both pharmacists and patients.

Advanced Infusion Pump Technology

Smart pumps with integrated safety software are minimizing medication errors and simplifying the treatment process for caregivers and patients. In April 2024, Baxter received FDA approval for its Novum IQ large-volume infusion pump and Dose IQ Safety Software, reinforcing the role of connected devices in improving home-based care.

These innovations are transforming home infusion therapy from a manual service into a data-driven, digitally supported healthcare solution.

Personalized Infusion Services Gain Momentum

Another key trend driving market growth is the increasing demand for customized infusion services tailored to individual patient needs. Specialty infusion services now address complex conditions such as multiple sclerosis, autoimmune diseases, rare disorders, and oncology treatments.

In February 2024, Dynamic Access launched Dynamic Infusion, a specialty home infusion nursing service supporting patients with long-term conditions. By partnering with over 35 specialty pharmacies, the company now delivers more than 10,000 home visits annually across nine U.S. states—demonstrating how personalized care models are scaling rapidly.

Challenges: Reimbursement Gaps and Regulatory Complexity

Despite strong growth prospects, the home infusion therapy market faces several obstacles.

Limited Reimbursement in Developing Markets

In many emerging economies, home infusion therapy is still largely paid out-of-pocket due to limited insurance coverage and reimbursement frameworks. Countries like India and China lack standardized reimbursement systems for home-based infusion care, which restricts patient access and slows adoption.

Regulatory and Compliance Barriers

Home infusion providers must comply with complex, region-specific regulations related to drug administration, patient safety, and insurance billing. Ensuring consistent care quality while meeting regulatory requirements remains a challenge, particularly for small or regional providers.

Workforce shortages, especially trained infusion nurses, further add to operational pressure.

Regional Market Insights: Growth Across Continents

North America: Market Leader

North America dominates the global home infusion therapy market due to its advanced healthcare infrastructure, favorable reimbursement policies, and high awareness of home-based care. The United States leads the region with strong government support and a large network of home health agencies.

In April 2023, Memorial Hermann Health System invested in KabaFusion, expanding home infusion services nationwide. Similarly, Amedisys completed a USD 3.60 billion merger with Optum Inc. in May 2023, strengthening its nationwide infusion capabilities.

Despite regulatory complexity and workforce challenges, the U.S. market remains the global benchmark for home infusion therapy.

Europe: Steady Expansion Driven by Aging Populations

Europe is experiencing consistent growth due to rising chronic disease prevalence and aging demographics. Countries like Germany, France, and the UK benefit from strong public healthcare systems that support home-based services.

Germany, in particular, has established reimbursement pathways for home infusion therapy, accelerating adoption. Although logistical and regulatory challenges persist, patient demand for home-based treatment continues to grow steadily.

Asia Pacific: Fastest-Growing Region

Asia Pacific represents the fastest-growing market due to increasing healthcare costs, urbanization, and chronic disease prevalence. Countries such as China, India, Japan, and Australia are investing heavily in home healthcare infrastructure.

India Home Infusion Therapy Market

India’s home infusion market is expanding due to rising cases of cancer, diabetes, and cardiovascular diseases. While infrastructure gaps, workforce shortages, and limited reimbursement remain barriers, growing awareness and digital health adoption are driving momentum. The shortage of hospital beds makes home infusion therapy a practical alternative, particularly in urban areas.

Middle East & Africa: Emerging Opportunities

Saudi Arabia is witnessing rapid growth supported by government healthcare reforms and medical technology investment. However, limited awareness and regulatory challenges continue to slow adoption. Despite this, the region holds significant long-term potential as healthcare modernization accelerates.

Market Segmentation Overview

By Product

Infusion Pumps

Intravenous Sets

IV Cannulas

Needleless Connectors

By Application

Anti-Infective Therapy

Hydration Therapy

Chemotherapy

Enteral Nutrition

Parenteral Nutrition

Specialty Pharmaceuticals

Others

By Geography

North America: U.S., Canada

Europe: Germany, France, UK, Italy, Spain, Belgium, Netherlands, Turkey

Asia Pacific: China, Japan, India, South Korea, Australia, Southeast Asia

Latin America: Brazil, Mexico, Argentina

Middle East & Africa: Saudi Arabia, UAE, South Africa

Key Players Shaping the Market

The global home infusion therapy market is highly competitive, with companies focusing on innovation, partnerships, and geographic expansion. Key players analyzed across five viewpoints (overview, product portfolio, strategy, recent developments, and revenue) include:

Pfizer Inc.

Smith & Nephew plc

Terumo Corporation

Johnson & Johnson Services, Inc.

Becton, Dickinson and Company

Baxter International Inc.

ICU Medical

Eli Lilly and Company

These companies are investing heavily in smart infusion devices, digital health integration, and service expansion to capture growing demand.

Final Thoughts: The Future of Infusion Therapy Is at Home

The global home infusion therapy market is entering a decisive growth phase. With rising chronic disease burden, aging populations, and healthcare systems under cost pressure, the shift toward home-based infusion care is no longer optional—it is inevitable.

Technological advancements, favorable policies, and patient-centric care models are accelerating adoption worldwide. While reimbursement gaps and regulatory challenges remain, especially in developing markets, innovation and investment continue to close these gaps.

By 2033, home infusion therapy will not just complement hospital care—it will redefine how long-term treatment is delivered globally, making healthcare more accessible, affordable, and humane.